Novartis Halts CAR T-Cell Trials Following Patient Deaths in Experimental Therapy

September 6, 2026

pharmaphorum USA

Overview

Novartis has temporarily halted eight clinical trials for its experimental CAR T-cell therapy, rapcabtagene autoleucel (rap-cel), following the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS). Concurrently, Bristol Myers Squibb has voluntarily paused enrollment in trials for its CD19-targeted CAR T-cell therapy, zolacabtagene autoleucel (zola-cel), for autoimmune diseases. These decisions raise significant industry-wide concerns regarding the safety profile of CAR T-cell therapies, particularly in relation to rapid manufacturing platforms.

In Depth

Key Finding: Novartis Halts CAR T-Cell Therapy Trials for rap-cel Following Patient Deaths

Novartis has temporarily paused eight clinical trials for its investigational CAR T-cell therapy, rapcabtagene autoleucel (rap-cel), following the deaths of three patients from severe, life-threatening immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS). This incident raises new concerns about the safety profile of CAR T-cell therapies, particularly in their application for autoimmune diseases.

Clinical Details: Severe Adverse Events and Manufacturing Platform Implications

IEC-HS, a severe inflammatory condition caused by uncontrolled immune cell activation, is a known side effect of CAR T-cell therapies. This tragic event prompts intense scrutiny from regulatory bodies and the industry regarding rap-cel’s safety data, especially in connection with the rapid manufacturing platforms utilized to produce the cells. Novartis is currently conducting a comprehensive investigation to identify the root causes of these events and to determine the feasibility of resuming the trials.

Background and Industry Context: Emerging Challenges in Autoimmune CAR T-Therapy

While CAR T-cell therapies have achieved transformative success in treating hematological cancers, their application in autoimmune diseases is still in its nascent stages, where unexpected safety challenges can emerge. Concurrently, Bristol Myers Squibb (BMS) has also voluntarily suspended enrollment in trials for its CD19-targeted CAR T-cell therapy, zolacabtagene autoleucel (zola-cel), for autoimmune diseases. Industry experts are pointing to the potential involvement of “rapid manufacturing” or “short-duration manufacturing” processes, which might influence cell phenotype and function, contributing to these safety concerns across the autoimmune CAR T landscape.

Future Outlook: Enhanced Safety and Manufacturing Process Review

These trial pauses underscore the critical need for more rigorous safety data evaluation and improved risk management strategies in the development of CAR T-cell therapies for autoimmune diseases. Moving forward, Novartis and BMS will likely investigate the mechanisms of adverse event occurrence and explore strategies to enhance safety through adjustments in cell design, preconditioning regimens, and manufacturing processes. The lessons learned from these incidents are expected to provide invaluable insights for establishing the optimal balance between safety and efficacy in future cell therapy development.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.